JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Role of hyperforin in diabetes and its associated hyperlipidemia in rats
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : TANG [HUMANITAS MEDICINE]
  • Volume 2, Issue 3,  2012, pp.25.1-25.6
  • Publisher : Association of Humanitas Medicine
  • DOI : 10.5667/tang.2012.0015
 Title & Authors
Role of hyperforin in diabetes and its associated hyperlipidemia in rats
Ineedi, Srikanth; Shakya, Anshul; Singh, Gireesh Kumar; Kumar, Vikas;
  PDF(new window)
 Abstract
The aim of the present study was to evaluate the possible roles of hyperforin against hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats. Diabetes was induced by a single intraperitoneal injection of streptozotocin (65 mg/kg). Biochemical parameters were measured following hyperforin treatment (10 mg/kg, i.p.) for 7 days. Hyperforin treatment significantly reversed the elevations in plasma glucose, triglycerides, total cholesterol and LDL-cholesterol. Hyperforin also reversed the declines in plasma HDL-cholesterol and liver glycogen, but did not reverse the change in plasma insulin levels when compared to the diabetic control rats. Hyperforin treatment also reversed the oxidative stress induced by streptozotocin. Moreover, the effect of the hyperforin on peripheral glucose utilization in normal rats was evaluated by an oral glucose tolerance test (OGTT). Hyperforin treatment significantly increased (p < 0.05) the glucose tolerance compared to the vehicle in OGTT. The antihyperglycemic, antihyperlipidemic and antioxidant activities of hyperforin (10 mg/kg, i.p.) were comparable qualitatively to glibenclamide (1 mg/kg, p.o.). In conclusion, we report for the first time through an in vivo study that hyperforin is potentially valuable for the treatment of diabetes and its associated hyperlipidemia and oxidative stress by enhancing the glucose utilization by peripheral tissues such as muscle and adipose tissues.
 Keywords
hyperforin;diabetes;insulin;antihyperglycemic;antihyperlipidemic;antioxidant;
 Language
English
 Cited by
 References
1.
Akah PA, Alemji JA, Salawu OA, Okoye TC, Offiah NV. Effects of Vernonia amygdalina on Biochemical and Hematological Parameters in Diabetic Rats. Asian J Med Sci. 2009;1:108-113.

2.
Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002;64:1767-1775. crossref(new window)

3.
Alberti KGMM, Zimmet P, DeFronzo RA. International Textbook of Diabetes Mellitus. (New York, USA: John Wiley and Sons), 1997.

4.
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412. crossref(new window)

5.
Beerhues L. Molecules of interest: Hyperforin. Phytochem. 2006;67:2201-2207. crossref(new window)

6.
Cetto AA, Wiedenfeld H, Revilla MC, Sergio IA. Hypoglycemic effect of Equisetum myriochaetum aerial parts on STZ diabetic rats. J Ethnopharmacol. 2000;72:129-133. crossref(new window)

7.
Chan O, Inouye K, Vranic M, Matthews SG. Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin diabetic rats is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity. Endocrinol. 2002;143:1761-1768. crossref(new window)

8.
Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci. 1998a;63:499-510. crossref(new window)

9.
Chatterjee SS, Nöldner M, Koch E, Erdelmeier C. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry. 1998b;31:7-15. crossref(new window)

10.
Chrousos GP, Gold PW. The concepts of stress system disorders: overview of behavioral and physical homeostasis. J Am Med Assoc. 1992;267:1244-1252. crossref(new window)

11.
Derijks HJ, Meyboom RH, Heerdink ER, Koning FHPD, Janknegt R, Lindquist M, Egberts ACG. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol. 2008;64:531-538. crossref(new window)

12.
Dubey GP, Pandey E, Tripathi YB. Antioxidant property of Hypericum perforatum (L.) of Indian origin and its comparison with established Medhya rasayanas of ayurvedic medicine. Curr Sci. 1999;76:27-29.

13.
Duntas L, Kolovou G. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Future Cardiol. 2011;7:137-144. crossref(new window)

14.
El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary EES. Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnesic dose of scopolamine. Pharmacol Biochem Behav. 2003;76:525-533. crossref(new window)

15.
Feisst C, Werz O. Suppression of receptor-mediated $Ca^{2+}$ mobilization and functional leukocyte responses by hyperforin. Biochem Pharmacol. 2004;67:1531-1539. crossref(new window)

16.
Ganster RW, Taylor BS, Shao L, Geller, DA. Complex regulation of human inducible nitric oxide synthase gene transcription by STAT-1 and NF-kB. Proc Natl Acad Sci USA. 2001;98:8638-8643. crossref(new window)

17.
Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36:232-240. crossref(new window)

18.
Gioti EM, Fiamegos YC, Skalkos DC, Stalikas CD. Antioxidant activity and bioactive components of the aerial parts of Hypericum perforatum L. from Epirus, Greece. Food Chem. 2009;117:398-404. crossref(new window)

19.
Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetes vascular complications. Diabetes Care. 1996;19:257-267. crossref(new window)

20.
Heilmann J, Winkelmann K, Sticher O. Studies on the antioxidative activity of phloroglucinol derivatives isolated from hypericum species. Planta Med. 2003;69:202-206. crossref(new window)

21.
Husain GM, Chatterjee SS, Singh PN, Kumar V. Antiaggressive activity of standardized extract of Indian Hypericum perforatum L. Pharmacologyonline. 2009a;1:432-444.

22.
Husain GM, Singh PN, Kumar V. Antidiabetic activity of Indian Hypericum perforatum L. on alloxan induced diabetic rats. Pharmacologyonline. 2008;3:889-894.

23.
Husain GM, Singh PN, Kumar V. Beneficial effects of a standardized Hypericum perforatum extract in rats with experimentally induced hyperglycemia. Drug Discov Ther. 2009b;3:215-220.

24.
Husain GM, Singh PN, Singh RK, Kumar V. Antidiabetic activity of standardized extract of Quassia amara in nicotinamide-streptozotocin‐induced diabetic rats. Phytother. Res. 2011;25:1806-1812. crossref(new window)

25.
Ineedi S, Kumar V. Anti-hyperlipidemic activity of hyperforin: An in vivo study in rats. Pharmacologyonline. 2009;2:133-139.

26.
Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys. 1984;21:130-132.

27.
Katon WJ. The comorbidity of diabetes mellitus and depression. Am J Med. 2008;121:S8-S15.

28.
Kumar V, Chatterjee S.S. Ethnopharmacology and rational evaluation of herbal remedies. In: Handbook of Ethnopharmacology, Eddouks Med. (Trivandrum, India: Research Signpost Publishers), pp 25-50, 2008.

29.
Kumar V, Khanna VK, Seth PK, Singh PN, Bhattacharya SK. Brain neurotransmitter receptor binding and nootropic studies in Indian Hypericum perforatum Linn. Phytother Res. 2002;16:210-216. crossref(new window)

30.
Kumar V, Singh PN, Bhattacharya SK. Anti-stress activity of Indian Hypericum perforatum L. Indian J Exp Biol. 2001;39:344-349.

31.
Kumar V, Singh PN, Bhattacharya SK. Neuropsychopharm acological studies on Indian Hypericum perforatum Linn. In: Medicinal and aromatic plants- Industrial profile, Volume genus Hypericum, Ernst E ed. (New York, USA: Taylor & Francis), pp 179-226, 2003.

32.
Kumar V, Singh PN, Jaiswal AK, Bhattacharya SK. Antidepressant activity of Indian Hypericum Perforatum Linn in rodents. Indian J Exp Biol. 1999;37:1171-1176.

33.
Kumar V, Singh PN, Muruganandam AV, Bhattacharya SK. Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction. J Ethnopharmacol. 2000;72:119-128. crossref(new window)

34.
Lakkmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998;31:54-59. crossref(new window)

35.
Lang F, Biber A, Erdelmeier C. Hyperforin in St. John's wort--drug, extraction and preparations. Pharm Unserer Zeit. 2002;5:512-514.

36.
Lowry OH, Rosenborough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem. 1951;193:265-275.

37.
Lustman PJ, Clouse RE. Depression in diabetes patients: the relationship between depression and diabetes in adults. J Diabetes Complications. 2005;19:113-122.

38.
Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol. 2003;66:1433-1440. crossref(new window)

39.
Medina MA, Martinez-Poveda B, Amores-Sanchez MI, Quesada A.R. Hyperforin: More than an antidepressant bioactive compound? Life Sci. 2006;79:105-111. crossref(new window)

40.
Menegazzi M, Novelli M, Beffy P, D'Aleo V, Tedeschi E, Lupi R, Zoratti E, Marchetti P, Suzuki H, Masiello P. Protective effects of SJW extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic ${\beta}$-cell line. Int J Biochem Cell Biol. 2008;40:1509-1521. crossref(new window)

41.
Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes type 1 and type 2: epidemiology, biology and treatment. Biol Psychiatry. 2003;54:317-329. crossref(new window)

42.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Bioche. 1979;95:351-358. crossref(new window)

43.
Radahmadi M, Shadan F, Karimian SM, Sadr SS, Nasimi A. Effects of stress on exacerbation of diabetes mellitus, serum glucose and cortisol levels and body weight in rats. Pathophysiology. 2006;13:51-55. crossref(new window)

44.
Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007;120:S12-S18.

45.
Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001;17:189-212. crossref(new window)

46.
Roy M, Collier B, Roy A. Hypothalamic-pituitary-adrenal axis dysregulation among diabetic outpatients. Psychiatry Res. 1990;31:31-37. crossref(new window)

47.
Sanchez-Reus MI, Gomez DR, Iglesias I, Elorza M, Slowing K, Benedi J. Standardized Hypericum perforatum reduces oxidative stress and increases gene expression of antioxidant oxidant enzymes in rotenone exposed rats. Neuropharmacology. 2007;52:606-616. crossref(new window)

48.
Schwarz D, Kisselev P, Roots, I. St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo [a]pyrene-7, 8-dihydrodiol by human CYP1A1. Cancer Res. 2003;63:8062-8068.

49.
Scott M, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR. Diabetes and Cardiovascular Disease. Circulation. 1999;100:1134-1146. crossref(new window)

50.
Sharma B, Balomajumder C, Roy P. Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats. Food Chem Toxicol. 2008;46:2376-2383. crossref(new window)

51.
Silva BA, Malva JO, Dias ACP. SJW (Hypericum perforatum) extracts and isolated phenolic compounds are effective antioxidants in several in vitro models of oxidative stress. Food Chem. 2008;110:611-619. crossref(new window)

52.
Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin reuptake by elevating free intracellular $Na^{+}$. J Pharmacol Exp Ther. 1999;290:1363-1368.

53.
Sinha AK. Colorimetric assay of catalase. Anal Biochem. 1972;47:389-394. crossref(new window)

54.
Stefan ND. Insulin, oral hypoglycemic agents, and the pharmacology of endocrine pancreas. Goodman and Gilman's text book of the pharmacological basis of therapeutics, (Columbus, USA: The McGraw-Hill companies), pp 611-613, 2005.

55.
Strachan MWJ, Deary IJ, Ewing FME, Frier BM. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetic Care. 1997;20:438-445. crossref(new window)

56.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50:536-546.

57.
Vies JVD. Two Methods for the determination of glycogen in liver. Biochem J. 1953;57:410-416.